新型冠状病毒疫苗与癫痫相关研究进展_Journal of Epilepsy

Authors：

刘家琪 ^1,2,3 , 杨逸昊 ^1,2 , 王胜 ^1,2 , 童婧怡 ^1,2 , 马琳 ^1,2 , 蔡毅 ^1,2 ,  李其富 ^1,2,3

1. ;
2. ;
3. ;

Corresponding author：

李其富, Email: lee-chief@163.com

Keywords：

新型冠状病毒疫苗; 癫痫; 研究进展

DOI：

10.7507/2096-0247.20210053

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

新型冠状病毒肺炎（Coronavirus disease 2019，COVID-19）目前仍在世界范围内呈现大流行的趋势，随着病毒的肆意蔓延及迅速变异，针对新冠病毒的疫苗研发工作也在不断深入。癫痫患者作为新冠疫苗的慎用人群，其适用条件的探究也在随着患者需求的增加而日渐清晰。目前已有相关指南对癫痫患者能否接种新冠疫苗给出初步建议，但针对患者个体情况的具体应用条件尚未明确。现有研究表明，目前已上市投入使用的疫苗中，接种后的神经系统不良反应虽存在，但癫痫患者并非疫苗接种的绝对禁忌人群。本文主要就新型冠状病毒疫苗针对癫痫患者的具体适用条件及相关建议作一综述。

Citation： 刘家琪, 杨逸昊, 王胜, 童婧怡, 马琳, 蔡毅, 李其富. 新型冠状病毒疫苗与癫痫相关研究进展. Journal of Epilepsy, 2021, 7(4): 327-334. doi: 10.7507/2096-0247.20210053 Copy

1.	Sun Y, Christensen J, Hviid A, et al. Risk of febrile seizures and epilepsy after vaccination with diphtheria, tetanus, acellular pertussis, inactivated poliovirus, and haemophilus influenzae type b. JAMA, 2012, 307(8): 823-831.
2.	Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis, 2021, 21(2): 181-192.
3.	Zhu FC, Guan XH, Li YH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet, 2020, 396(10249): 479-488.
4.	Keech C, Albert G, Cho I, et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med, 2020, 383(24): 2320-2332.
5.	Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med, 2020, 383(27): 2603-2615.
6.	Ella R, Vadrevu KM, Jogdand H, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. Lancet Infect Dis, 2021, 21(5): 637-646.
7.	Ella R, Reddy S, Jogdand H, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. Lancet Infect Disease, 2021, S1473-3099(21): 00070-0.
8.	Voysey Merryn et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet, 2020, 397(10269): 99-111.
9.	Chu Laurence et al. A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. Vaccine, 2021, 39(20): 2791-2799.
10.	Doroftei Bogdan et al. Mini-review discussing the reliability and efficiency of COVID-19 vaccines. Diagnostics, 2021, 11(4): 579.
11.	Logunov Denis Y et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet, 2021, 397(10275): 671-681.
12.	Xia Shengli et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA, 2020, 324(10): 951-960.
13.	Sadoff Jerald et al. Interim results of a phase 1–2a trial of Ad26. COV2. S Covid-19 vaccine. New England Journal of Medicine, 2021, 384(19): 1824-1835.
14.	Xiang Wang. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine, 2021, 384(16): 1576-1578.
15.	中国抗癫痫协会. 临床诊疗指南癫痫病分册(2015修订版)[M]. 北京: 人民卫生出版社, 2015: 15-16.
16.	Deng L, Wood N, Danchin M. Seizures following vaccination in children: Risks, outcomes and management of subsequent revaccination. Aust J Gen Pract, 2020, 49(10): 644-649.
17.	叶盛. 特殊健康状态儿童预防接种专家共识之八——癫痫与预防接种. 中国实用儿科杂志, 2019, 34(02): 82-84.
18.	Reyes IS, Hsieh DT, Laux LC, et al. Alleged cases of vaccine encephalopathy rediagnosed years later as Dravet syndrome. Pediatrics, 2011, 128(3): e699-702.

1. Sun Y, Christensen J, Hviid A, et al. Risk of febrile seizures and epilepsy after vaccination with diphtheria, tetanus, acellular pertussis, inactivated poliovirus, and haemophilus influenzae type b. JAMA, 2012, 307(8): 823-831.
2. Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis, 2021, 21(2): 181-192.
3. Zhu FC, Guan XH, Li YH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet, 2020, 396(10249): 479-488.
4. Keech C, Albert G, Cho I, et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med, 2020, 383(24): 2320-2332.
5. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med, 2020, 383(27): 2603-2615.
6. Ella R, Vadrevu KM, Jogdand H, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. Lancet Infect Dis, 2021, 21(5): 637-646.
7. Ella R, Reddy S, Jogdand H, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. Lancet Infect Disease, 2021, S1473-3099(21): 00070-0.
8. Voysey Merryn et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet, 2020, 397(10269): 99-111.
9. Chu Laurence et al. A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. Vaccine, 2021, 39(20): 2791-2799.
10. Doroftei Bogdan et al. Mini-review discussing the reliability and efficiency of COVID-19 vaccines. Diagnostics, 2021, 11(4): 579.
11. Logunov Denis Y et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet, 2021, 397(10275): 671-681.
12. Xia Shengli et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA, 2020, 324(10): 951-960.
13. Sadoff Jerald et al. Interim results of a phase 1–2a trial of Ad26. COV2. S Covid-19 vaccine. New England Journal of Medicine, 2021, 384(19): 1824-1835.
14. Xiang Wang. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine, 2021, 384(16): 1576-1578.
15. 中国抗癫痫协会. 临床诊疗指南癫痫病分册(2015修订版)[M]. 北京: 人民卫生出版社, 2015: 15-16.
16. Deng L, Wood N, Danchin M. Seizures following vaccination in children: Risks, outcomes and management of subsequent revaccination. Aust J Gen Pract, 2020, 49(10): 644-649.
17. 叶盛. 特殊健康状态儿童预防接种专家共识之八——癫痫与预防接种. 中国实用儿科杂志, 2019, 34(02): 82-84.
18. Reyes IS, Hsieh DT, Laux LC, et al. Alleged cases of vaccine encephalopathy rediagnosed years later as Dravet syndrome. Pediatrics, 2011, 128(3): e699-702.

Previous Article
癫痫患者与新型冠状病毒肺炎疫苗：专家建议
Next Article
儿童良性癫痫伴中央颞区棘波的研究进展

Journal of Epilepsy

新型冠状病毒疫苗与癫痫相关研究进展

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content